We can advance innovation in organ transplant care
Together with you and other partners in the ProActive Study, we will generate insights that enable earlier, more precise assessment of allograft rejection. Over time, these insights hold the promise to improve the lives of transplant patients everywhere.
Let’s improve the management of transplant patients
Management through effective use of biopsy
Outcomes including improved graft survival
Ability to identify subclinical and clinical rejection compared to serum creatinine
Proactive Study Eligibility
- Must be willing to provide informed consent
- Must be a kidney transplant recipient
- From 60 days post-transplant to up to two years post-transplant
- Other non-kidney transplanted organ(s)
- Genetically identical donor organs
- RNA biomarker test after enrollment
Together, we can help patients thrive and prosper
We need your help. Natera is applying its experience of performing over 3 million cell-free DNA tests in the prenatal setting to the complex world of transplantation. Thought leaders like you are essential to successfully advancing the management of post-kidney transplantation through innovation. Your participation in the ProActive Study contributes to the exploration of cell-free DNA’s potential to assess the health of a transplanted organ.